Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722146 · ClinicalTrials.gov registry record · Phase 1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT04722146 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 140 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04722146, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Bortezomib
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Fitzroy
- Alfred Health - Melbourne
- Calvary Mater Newcastle Hospital - Waratah
- UZA - Edegem
- UZ Gent - Ghent
- Centre Leon Berard - Lyon
New York
- Memorial Sloan-Kettering Cancer Center - New York
- Weill Cornell Medical College - New York
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Winship Cancer Institute Emory University - Atlanta
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Missouri
- Washington University School Of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-03-12 |
| Est. Completion | 2027-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04722146
The ClinicalTrials.gov registry entry for NCT04722146 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT04722146 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04722146 about?
NCT04722146 is a clinical study titled "A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma". The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
What is the current status of trial NCT04722146?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-03-12. Estimated completion is 2027-10-05.
What conditions does trial NCT04722146 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04722146?
The interventions under investigation include: Teclistamab (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04722146?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04722146 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.